Compare GlobalFoundries Inc. Ordinary Shares (GFS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GlobalFoundries Inc. Ordinary Shares vs Repligen Corporation Common Stock — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $48.01 (market cap $26.95B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: GlobalFoundries Inc. Ordinary Shares is far larger — about 2.4× Repligen Corporation Common Stock's market cap, and GlobalFoundries Inc. Ordinary Shares pays a 0.99% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 1 Days and Repligen Corporation Common Stock for 0 Days on average.
| GFS | RGEN | |
|---|---|---|
Market Cap | $26.95B | $11.14B |
Volume | 7,717,478 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $89.96 | $194.57 |
52-Week Low | $32.24 | $102.87 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $26.24B | $11.02B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GlobalFoundries (GFS) trades at $46.70, down 3.39% on the day, with technical indicators showing a neutral to bearish short-term bias. The company maintains solid fundamentals with $6.79B revenue and 10.32% net margin, though profitability declined year-over-year. Recent catalysts include a landmark $21B Japan-backed fab expansion and strategic partnerships with TSMC and Marvell for AI-related semiconductor production, positioning GFS for long-term growth in the semiconductor sector.
While near-term technical weakness persists, GFS's strategic positioning in AI infrastructure and substantial government-backed expansion create compelling long-term opportunities. Risks include execution challenges with massive capital projects and semiconductor cycle volatility. With 57.9% analyst buy ratings and a $79.69 consensus target representing 71% upside, Wall Street remains optimistic about GFS's growth trajectory despite current market softness.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GlobalFoundries Inc. Ordinary Shares
GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.
Read more on GFS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
